Clinical trial
Treatment of Early Onset Schizophrenia Spectrum Disorders (TEOSS)
NCT00053703 · University of North Carolina, Chapel Hill, Other · Completed
Key facts
| NCT number | NCT00053703 |
|---|---|
| Title | Treatment of Early Onset Schizophrenia Spectrum Disorders (TEOSS) |
| Official title | Treatment of Schizophrenia and Related Disorders in Children and Adolescents |
| Acronym | TEOSS |
| Lead sponsor | University of North Carolina, Chapel Hill, Other |
| Collaborators | National Institute of Mental Health (NIMH) NIH |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Schizophrenia |
| Intervention type | Drug |
| Interventions | Risperidone, Olanzapine (enrollment closed in this treatment), Molindone |
| Enrollment | 116 |
| Start date | Feb 1, 2002 |
| Primary completion | May 1, 2007 |
| Completion | May 1, 2007 |
| First posted | Feb 5, 2003 |
| Last update posted | Mar 26, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: